ONC — Oncolytics Biotech Share News
0.000.00%
Last trade - 00:00- CA$138.32m
- CA$123.56m
Brief: Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Brief: Oncolytics Biotech Advances Toward Registration-Enabling Trial For Pelareorep In Breast Cancer With Submission Of Type C Meeting Request To FDA
Brief: Oncolytics Biotech Advances Toward Registration-Enabling Trial For Pelareorep In Breast Cancer With Submission Of Type C Meeting Request To FDA
Brief: Oncolytics Biotech Announces Presentation at Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
Brief: Oncolytics Biotech Initiates Enrollment Expansion Of GOBLET Anal Cancer Cohort
Brief: Oncolytics Biotech Appoints Patricia S. Andrews To Its Board Of Directors
Brief: Oncolytics Biotech Appoints Patricia S. Andrews To Its Board Of Directors
Brief: Oncolytics Biotech Says Co Expects To Initiate First Phase 3 Study for Pelareorep In Pancreatic Cancer In 2024
Brief: Oncolytics Announces Anal Cancer Cohort Of GOBLET Phase 1/2 Study Of Pelareorep And Atezolizumab Met Success Criteria For Efficacy
Brief: Oncolytics Provides Update On Pancreatic Cancer Program For Pelareorep
Brief: Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study
Brief: The Pancreatic Cancer Action Network Selects Oncolytics Biotech Inc. To Receive $5 Million Therapeutic Accelerator Award To Develop Leading-Edge Treatments
Oncolytics down on bigger-than-expected Q2 loss
Brief: Oncolytics Biotech's Pelareorep Selected For Inclusion In Precision PromiseSM Pivotal Phase 3 Platform Trial
Canada Research Roundup: Emera, Keyera, Oncolytics Biotech
Brief: Oncolytics Biotech Reports $29.7 Million In Cash, Cash Equivalents, Marketable Securities As Of March 31, Provides Projected Cash Runway For At Least 12 Months
Brief: Oncolytics Biotech Reports Q4 Loss Per Share Of C$0.14
Oncolytics jumps as FDA grants 'fast track' tag for pancreatic cancer therapy
Oncolytics gains as FDA grants 'fast track' tag for pancreatic cancer therapy